[187 Pages Report] The RNA Therapy Market size was estimated at USD 2.18 billion in 2023 and expected to reach USD 2.60 billion in 2024, at a CAGR 22.38% to reach USD 8.98 billion by 2030.
RNA therapy includes developing and commercializing therapeutic approaches that utilize ribonucleic acid (RNA) molecules to target specific genetic sequences and cellular mechanisms. These therapies treat various diseases and conditions by replacing faulty genes, silencing harmful gene expressions, or modulating cellular functions by targeting RNA molecules. Increasing investments in biotechnology startups, growing collaborations between academia and industry players, and an expanding portfolio of potential therapeutic targets for unmet medical needs drive the need for RNA therapies. Favorable regulatory policies for orphan drug designation and fast-track approvals have accelerated the clinical development of several RNA-based therapies. Delivery challenges associated with instability and rapid degradation of RNA molecules in vivo hampers market growth. Ongoing advancements by pharmaceutical companies to leverage cutting-edge technologies into novel RNA treatments for rare diseases with limited treatment options are expected to create opportunities for market growth.
Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
Enabled technology drives the advancement in RNA therapy as it provides the tools necessary for precisely manipulating and delivering RNA molecules to target cells. This technology silences specific genes by introducing small interfering RNAs (siRNAs) into cells. Enabling technologies facilitate the development and application of enabled technologies by providing improved RNA molecule design, synthesis, modification, and delivery methods. Enabled technologies such as RNA interference (RNAi), Antisense Oligonucleotides (ASOs), and messenger Ribonucleic Acid (mRNA) therapeutics offer different approaches to modulating gene expression depending on the targeted disease mechanism.
Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
RNA therapy is crucial in cancer treatment by targeting specific oncogenes or tumor suppressor genes. These therapies help to regulate gene expression, which is often disrupted in cancerous cells. Need-based preference for RNA therapy in cancer includes personalized treatments tailored to the patient’s genetic makeup. RNA therapy has potential applications for treating cardiovascular diseases such as heart failure and hypertension by modulating the expression of disease-related genes. Patients with severe or rare cardiovascular conditions may benefit from these targeted therapies as they offer fewer side effects and better efficacy compared to conventional treatments. RNA therapy can be used to treat genetic disorders caused by mutations or deficiencies in single genes. This need-based preference focuses on patients with rare, life-threatening genetic diseases with limited treatment options. By modulating host immune responses or directly targeting pathogens, RNA therapy can help combat viral and bacterial infections such as COVID-19, hepatitis B, and tuberculosis. Preference exists for patients suffering from drug-resistant infections or requiring rapid response treatments during outbreaks. RNA therapy provides new treatment options for chronic kidney diseases such as polycystic kidney disease and diabetic nephropathy by targeting specific genes involved in renal function and fibrosis. RNA therapy has the potential to treat metabolic disorders, including obesity, non-alcoholic steatohepatitis (NASH), and type 2 diabetes by regulating key genes involved in glucose and lipid metabolism. In addition to cancer vaccines, RNA therapy is used to develop personalized immunotherapies for various tumor types by encoding patient-specific tumor antigens. This need-based preference targets patients with aggressive or metastatic cancers that do not respond well to standard treatments. RNA therapy helps to treat retinal diseases caused by genetic mutations, such as Leber’s congenital amaurosis and age-related macular degeneration, by delivering functional copies of the affected genes directly into retinal cells.
End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
In academic research, RNA therapy is primarily utilized for understanding gene function and regulation. Researchers employ various RNA therapeutic approaches such as small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), microRNAs (miRNAs), and messenger RNA (mRNA) therapeutics. RNA-based diagnostics focuses on detecting disease-specific biomarkers through targeted sequencing or gene expression profiling. These diagnostic methods offer increased sensitivity compared to traditional DNA-based techniques. RNA-targeted drug discovery and development involve identifying novel therapeutic targets, designing selective RNA-binding small molecules or oligonucleotides, and developing innovative delivery systems to overcome cellular barriers.
Regional Insights
The RNA therapy market in the Americas is supported by a developed healthcare sector and supportive government programs, resulting in considerable commercialization of cutting-edge RNA therapies in the United States and Canada and the evolving pharmaceutical industry in South American countries. The governments in the Americas encourage technological advancements and research activities to provide a better healthcare system to people that contribute to overall economic growth and public welfare. The governments in the Asia-Pacific region’s emerging and developed economies, such as Japan, India, China, and South Korea, encourage research and development of RNA therapies. Europe has significantly adopted RNA therapies owing to the rapid commercialization and acceptability of new devices and technologies, enabling healthcare professionals to use RNA therapies. On the other hand, the surging geriatric population in Europe is expected to increase the indication of several infectious and chronic disorders. As per the Population Reference Bureau (PRB), Russia, Germany, Italy, France, the UK, Spain, Turkey, Ukraine, Poland, Nigeria, and Iran are some countries that have a significant percentage of the population aged over 65 years. The rising indication of Europe’s aging population and disorders necessitates efficient RNA therapies.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the RNA Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the RNA Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Deep Genomics, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Ionis Pharmaceuticals, Inc., Laronde, MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, Novartis AG, Novo Nordisk A/S, Nutcracker Therapeutics, Inc., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Triplet Therapeutics, Inc..
Market Segmentation & Coverage
This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Technology
- Enabled Technologies
- Inhibition
- Labeling
- Linear amplification
- Microarrays
- Purification
- qRT-PCR
- Enabling Technologies
- RNA Antisense Technologies
- MicroRNA
- Small interfering RNA
- RNA Interference Technologies
- RNA Antisense Technologies
- Enabled Technologies
- Indication
- Cancer
- Cardiovascular
- Genetic Disorders
- Infectious Diseases
- Kidney Diseases
- Metabolic Disorders
- Oncology
- Retinal Diseases
- End User
- Academic Research
- Diagnostics
- Drug Discovery & Development
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the RNA Therapy Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the RNA Therapy Market?
- What are the technology trends and regulatory frameworks in the RNA Therapy Market?
- What is the market share of the leading vendors in the RNA Therapy Market?
- Which modes and strategic moves are suitable for entering the RNA Therapy Market?
US $
Euro €
GBP £